Arcus Biosciences (RCUS) Cash from Operations (2017 - 2026)

Arcus Biosciences' Cash from Operations history runs 10 years deep, the most recent figure standing at 138000000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 4.55% year-over-year to 138000000.0 in Q1 2026; TTM through Mar 2026 was 488000000.0, a 62.67% decrease from a year earlier, with the FY2025 full-year figure at 482000000.0, down 183.53% from the prior year.
• Cash from Operations eased to 138000000.0 in Q1 2026 per RCUS's latest filing, from 120000000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 654000000.0 in Q1 2022 and bottomed at 138000000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 88000000.0 (2023), against an average of 38705882.35.
• Across the five-year window, Cash from Operations surged 1086.19% in 2022 and tumbled 6500.0% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 70000000.0 in 2022, then decreased by 25.71% to 88000000.0 in 2023, then slipped by 13.64% to 100000000.0 in 2024, then dropped by 20.0% to 120000000.0 in 2025, then retreated by 15.0% to 138000000.0 in 2026.
• Per Business Quant, the three latest RCUS Cash from Operations figures stand at 138000000.0 (Q1 2026), 120000000.0 (Q4 2025), and 97000000.0 (Q3 2025).